News: PRIME Program of EMA

2 additional drug candidates get access to PRIME of EMA:

1. CymaBay Therapeutics Announces that MBX-8025 has Received European Medicines Agency PRIority MEdicines (PRIME) Designation for the Treatment of Primary Biliary Cholangitis:

globenewswire.com/news-rele...

2. Albireo Pharma, Inc. (NASDAQ:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today that its lead product candidate, A4250, has been granted access to the PRIority MEdicines (PRIME) program of the European Medicines Agency (EMA) for the treatment of progressive familial intrahepatic cholestasis (PFIC).

globenewswire.com/news-rele...

Minutes for the meeting on 10 -13 October 2016:

ema.europa.eu/docs/en_GB/do...

1 Reply

oldestnewest
  • Great news that those who do no / can not benefit from urso UDCA (and possibly those who do) may have another weapon in the armoury. Also good to hear that research and development in this area is alive and well and producing results.

You may also like...